Multicenter Early Access Program Results from Turkey: Efficacy and Safety of Daratumumab Among Heavily Pretreated Relapse/Refractory Multiple Myeloma Patients

dc.contributor.author	Besisik, Sevgi
dc.contributor.author	Cagirgan, Seckin
dc.contributor.author	Yagci, Munci
dc.contributor.author	Vural, Filiz
dc.contributor.author	Tuglular, Tulin F.
dc.contributor.author	Beksac, Meral
dc.contributor.author	Aydin, Yildiz
dc.contributor.author	Goker, Hakan
dc.contributor.author	Turgut, Mehmet
dc.date.accessioned	2021-03-05T14:13:15Z
dc.date.available	2021-03-05T14:13:15Z
dc.identifier.citation	Beksac M., Aydin Y., Goker H., Turgut M., Besisik S., Cagirgan S., Tuglular T. F. , Vural F., Yagci M., "Multicenter Early Access Program Results from Turkey: Efficacy and Safety of Daratumumab Among Heavily Pretreated Relapse/Refractory Multiple Myeloma Patients", 59th Annual Meeting of the American-Society-of-Hematology (ASH), Georgia, Amerika Birleşik Devletleri, 9 - 12 Aralık 2017, cilt.130
dc.identifier.other	vv_1032021
dc.identifier.other	av_b61164cd-b3f4-430d-86f0-aa6578ac650b
dc.identifier.uri	http://hdl.handle.net/20.500.12627/121180
dc.language.iso	eng
dc.subject	Hematoloji
dc.subject	HEMATOLOJİ
dc.subject	Klinik Tıp
dc.subject	Health Sciences
dc.subject	Klinik Tıp (MED)
dc.subject	Tıp
dc.subject	Sağlık Bilimleri
dc.subject	Dahili Tıp Bilimleri
dc.subject	İç Hastalıkları
dc.subject	Hematology
dc.title	Multicenter Early Access Program Results from Turkey: Efficacy and Safety of Daratumumab Among Heavily Pretreated Relapse/Refractory Multiple Myeloma Patients
dc.type	Bildiri
dc.contributor.department	, ,
dc.identifier.volume	130
dc.contributor.firstauthorID	2521763

Files in this item

Files	Size	Format	View
There are no files associated with this item.